Teva price target raised to $14 from $13 at Barclays

Barclays analyst Balaji Prasad raised the firm’s price target on Teva to $14 from $13 and keeps an Overweight rating on the shares following the Q4 results. The analyst views the 10% post-earnings selloff as overdone on apparent guidance disappointment and would buy the weakness. The firm thinks current valuation levels form a new floor, with 2023 earnings also likely the lowest for next three years.